The effect of tetrathiomolybdate on cytokine expression, angiogenesis, and tumor growth in squamous cell carcinoma of the head and neck

Arch Otolaryngol Head Neck Surg. 2005 Mar;131(3):204-11. doi: 10.1001/archotol.131.3.204.

Abstract

Objective: To assess the effect of tetrathiomolybdate on cytokine expression, angiogenesis, and tumor growth rate in human squamous cell carcinoma (SCC).

Design: Three human SCC cell lines were used in this study for both in vitro and in vivo investigations. Conditioned media from untreated and tetrathiomolybdate-treated cell lines were compared with regard to cytokine levels, endothelial cell chemotaxis, endothelial cell tubule formation, and migration and the ability to induce angiogenesis in a rat aortic ring array. In vivo UM-SCC-38 was seeded onto tissue-engineered scaffolds and surgically implanted into the flanks of immunodeficient mice. Tumor growth rates and the level of angiogenesis were compared after 2 weeks of therapy.

Setting: A tertiary care facility.

Results: In this study, we demonstrate that tetrathiomolybdate significantly decreases the secretion of interleukin 6 and basic fibroblast growth factor by head and neck SCC (HNSCC) cell lines in vitro. Furthermore, we demonstrate that tetrathiomolybdate significantly decreases the secretion of interleukin 6 and basic fibroblast growth factor by HNSCC cell lines in vitro. Furthermore, tetrathiomolybdate treatment of HNSCC cell lines results in significantly decreased endothelial cell chemotaxis, tubule formation, and neovascularization in a rat aortic ring assay. This in vitro evidence of decreased angiogenesis by tetrathiomolybdate is confirmed in vivo by using a severe combined immunodeficiency disorder mouse model in which tetrathiomolybdate therapy is shown to prevent human blood vessel formation. Finally, human HNSCC implanted into immunodeficient mice grow to a much larger size in untreated mice compared with those treated with 0.7 mL/kg per day of oral tetrathiomolybdate.

Conclusions: These findings illustrate the ability of tetrathiomolybdate to down-regulate proinflammatory and proangiogenic cytokines in HNSCC. These observations are potentially exciting from a clinical perspective because a global decrease in these cytokines may decrease tumor aggressiveness and reverse the resistance to chemotherapy and radiation therapy seen in this tumor type.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Angiogenesis Inhibitors / pharmacology*
  • Animals
  • Biomarkers, Tumor / analysis
  • Biopsy, Needle
  • Carcinoma, Squamous Cell / pathology*
  • Cell Movement / drug effects
  • Cytokines / drug effects
  • Cytokines / metabolism*
  • Disease Models, Animal
  • Endothelial Cells / cytology
  • Endothelial Cells / drug effects
  • Enzyme-Linked Immunosorbent Assay
  • Head and Neck Neoplasms / pathology*
  • Humans
  • Immunohistochemistry
  • In Vitro Techniques
  • Mice
  • Mice, SCID
  • Molybdenum / pharmacology*
  • Neovascularization, Pathologic
  • Probability
  • Rats
  • Rats, Sprague-Dawley
  • Risk Assessment
  • Sensitivity and Specificity
  • Species Specificity
  • Tumor Burden / drug effects*
  • Tumor Cells, Cultured

Substances

  • Angiogenesis Inhibitors
  • Biomarkers, Tumor
  • Cytokines
  • Molybdenum
  • tetrathiomolybdate